Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKGP.L Regulatory News (KGP)

  • There is currently no data for KGP

Interim Management Statement

10 Nov 2014 07:00

RNS Number : 5259W
Kingspan Group PLC
10 November 2014
 

Kingspan Group Plc

Interim Management Statement

 

10 November 2014

 

Kingspan Group plc, the global leader in high performance insulation and building envelopes, today issues the following Interim Management Statement, with trading information for the period from 1 July to 30 September 2014.

 

Sales in the nine month period to 30 September were €1.39bn, up 5% on the prior year (+5% constant currency). A solid sales performance was also recorded in the third quarter with revenue up 7% (+5% constant currency) compared to the same period in 2013.

Insulated Panels revenue in the first nine months increased by 9% (+9% constant currency), and by 8% (+7% constant currency) in the third quarter. The UK continued to perform well with encouraging activity across most building segments. After a sluggish second quarter sales performance, Mainland Europe remained weak through the third quarter reflecting somewhat of an abatement in German market activity. The pace of sales growth in North America improved in the third quarter helped by a strong order book as we entered the second half. Order intake also showed a significant improvement over prior year. Activity in Australasia continued the strong trend evident in the first half.

Insulation Board revenue in the first nine months was up 3% (+1% constant currency) compared with the same period last year, and ahead by 6% in quarter three (+2% constant currency). The UK sales performance was positive through the third quarter, and Mainland European sales were relatively stable overall year on year. Further progress in market conversion was evident in Australia during the third quarter.

Environmental revenue in the first nine months was ahead of last year by 1% (-2% constant currency) and by 3% (-3% constant currency) in the third quarter, continuing on the path of relative stabilisation seen earlier in the year.

Access Floors revenue in the first nine months was 4% behind the same period last year (-4% constant currency). Sales in the third quarter were ahead by 11% (+8% constant currency) with continuing momentum evident in UK office construction activity and an improvement in the US relative to a weak first half.

 Net debt at the end of September 2014 was €107.7m, €39.1m lower than at the same point in 2013. The fourth quarter is a seasonally cash generative period and this would indicate net debt levels by year end in the region of €140m after taking account of the acquisitions of Pactiv Insulation (North America) and PAL (UAE). These insulation board businesses were separately acquired in October for a combined consideration of €77m.The relative optimism that prevailed earlier in the year appears to have waned in recent months, particularly in Europe. Whilst our business continues to perform solidly, we nonetheless are mindful of what are currently more tempered 2015 economic forecasts, and remain focused on driving the Kingspan proposition, whatever the macro climate.

The fourth quarter of 2013 was particularly strong for the Group. Notwithstanding that, and with this seasonally important and often variable period to come, we expect to deliver a full-year trading profit in the region of €144m (+17% versus 2013).

 

For further information contact:

 

Gene Murtagh, Chief Executive Officer Tel: +353 (0) 42 9698000

 

Geoff Doherty, Chief Financial Officer Tel: +353 (0) 42 9698000

 

Douglas Keatinge, Murray Consultants Tel: +353 (0) 1 4980300

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDBGUGBGSR
Date   Source Headline
18th Aug 20237:05 amRNSDelisting from the London Stock Exchange
18th Aug 20237:00 amRNSHalf-year Report
20th Jul 202311:37 amRNSResult of EGM
20th Jul 20239:56 amRNSHolding(s) in Company
18th Jul 20237:00 amRNSAcquisition
11th Jul 20237:00 amRNSTrading Update
3rd Jul 20232:40 pmRNSBlock listing Interim Review
3rd Jul 20232:34 pmRNSTotal Voting Rights
30th Jun 20234:54 pmRNSHolding(s) in Company
26th Jun 20232:00 pmRNSCircular and Notice of EGM
23rd Jun 20234:08 pmRNSHolding(s) in Company
14th Jun 20234:56 pmRNSHolding(s) in Company
14th Jun 20234:54 pmRNSHolding(s) in Company
1st Jun 20235:25 pmRNSTotal Voting Rights
2nd May 20235:09 pmRNSTotal Voting Rights
28th Apr 20234:07 pmRNSDirectorate Change
28th Apr 20234:00 pmRNSResult of AGM
28th Apr 20237:00 amRNSTrading Statement
3rd Apr 20234:40 pmRNSTotal Voting Rights
30th Mar 20239:00 amRNSDirector/PDMR Shareholding
21st Mar 20235:24 pmRNSDirector/PDMR Shareholding
20th Mar 20235:29 pmRNSHolding(s) in Company
20th Mar 20235:28 pmRNSHolding(s) in Company
16th Mar 20234:29 pmRNSHolding(s) in Company
16th Mar 20232:05 pmRNSNotice of AGM
1st Mar 20234:28 pmRNSTotal Voting Rights
1st Mar 20233:33 pmRNSHolding(s) in Company
1st Mar 202312:39 pmRNSDirector/PDMR Shareholding
28th Feb 20231:11 pmRNSDirector/PDMR Shareholding
24th Feb 20231:09 pmRNSHolding(s) in Company
23rd Feb 20234:57 pmRNSAnnual Financial Report
23rd Feb 20239:00 amRNSDirector/PDMR Shareholding
21st Feb 20235:34 pmRNSDirector/PDMR Shareholding
21st Feb 20235:28 pmRNSDirector/PDMR Shareholding
17th Feb 20237:30 amRNSDirectorate Change
17th Feb 20237:00 amRNSFinal Results
13th Feb 20236:02 pmRNSHolding(s) in Company
10th Feb 20233:00 pmRNSHolding(s) in Company
8th Feb 20234:35 pmRNSPrice Monitoring Extension
3rd Feb 20232:12 pmRNSHolding(s) in Company
2nd Feb 20234:27 pmRNSHolding(s) in Company
30th Jan 20232:48 pmRNSHolding(s) in Company
26th Jan 20234:40 pmRNSSecond Price Monitoring Extn
26th Jan 20234:35 pmRNSPrice Monitoring Extension
25th Jan 20234:05 pmRNSHolding(s) in Company
19th Jan 20237:00 amRNSHolding(s) in Company
17th Jan 20234:40 pmRNSHolding(s) in Company
3rd Jan 20239:05 amRNSBlock listing Interim Review
3rd Jan 20239:00 amRNSTotal Voting Rights
21st Dec 20224:14 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.